Management and treatment of patients with cirrhosis and portal hypertension: Recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program

American Journal of Gastroenterology

Volumn 104, Issue 7, 2009, Pages 1802-1829

  Garcia Tsao, Guadalupe ^a,b,c   Lim, Joseph ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY   (United States)

^c CT VA Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DIURETIC AGENT; FUROSEMIDE; ISOSORBIDE MONONITRATE; LACTULOSE; LEVOFLOXACIN; MIDODRINE; NADOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OCTREOTIDE; PARACETAMOL; PROPRANOLOL; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIFAXIMIN; SOMATOSTATIN; SORAFENIB; SPIRONOLACTONE; SULTAMICILLIN; TERLIPRESSIN; UNINDEXED DRUG; VAPREOTIDE;

ABDOMINAL CRAMP; ACUTE KIDNEY FAILURE; ANTIBIOTIC PROPHYLAXIS; ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BLOATING; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CHEMOEMBOLIZATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DIURETIC THERAPY; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; ENDOSCOPIC SCLEROTHERAPY; ENDOSCOPIC THERAPY; ENDOSCOPIC VARICEAL LIGATION; ESOPHAGUS ULCER; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FATIGUE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GYNECOMASTIA; HAND FOOT SYNDROME; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MORNING DOSAGE; MORTALITY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PARACENTESIS; PATIENT COMPLIANCE; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECOMMENDED DRUG DOSE; REVIEW; SCREENING TEST; SIDE EFFECT; TASTE DISORDER; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSARTERIAL CHEMOEMBOLIZATION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CAUSE OF DEATH; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATITIS C, CHRONIC; HEPATORENAL SYNDROME; HUMANS; HYPERTENSION, PORTAL; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION TESTS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 67650461998     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.191     Document Type: Review

References (256)

1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis. A systematic review of 118 studies . J Hepatol 2006;44:217-31.
2. Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding -unresolved issues. Summary of an American Association for the Study of Liver Diseases and European Association for the Study of the Liver Single-Topic Conference . Hepatology 2008 ; 47 : 1764-72.
3. Gines P, Quintero E, Arroyo V. Compensated cirrhosis: natural history and prognosis. Hepatology 1987;7:122-8.
4. de Franchis R. Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension . J Hepatol 2005 ; 43 : 167-76.
5. Garcia-Tsao G, Sanyal AJ, Grace ND et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis . Hepatology 2007;46:922-38.
6. Garcia-Tsao G, Sanyal AJ, Grace ND et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis . Am J Gastroenterol 2007 ; 102 : 2086-02.
7. Pagliaro L, DAmico G, Pasta L et al. Portal hypertension in cirrhosis: natural history . In: Bosch J, Groszmann RJ (eds). Portal Hypertension. Pathophysiology and Treatment . Blackwell Scientific: Oxford, 994 pp. 72-92.
8. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the frst variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study . N Engl J Med 1988 ; 319 : 983-9.
9. DAmico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach . Semin Liv Dis 1999 ; 19 : 475-505.
10. Chen W, Nikolova D, Frederiksen SL et al. Beta-blockers reduce mortality in cirrhotic patients with oesophageal varices who have never bled (Co-chrane review) . J Hepatol 2004 ; 40 (Suppl 1) : 67 (abstract) .
11. Merkel C, Marin R, Angeli P et al. A placebo-controlled clinical trial of na-dolol in the prophylaxis of growth of small esophageal varices in cirrhosis . Gas troenterology 2004;27:476-84.
12. Khuroo MS, Khuroo NS, Farahat KL et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding . Aliment Pharmacol Ther 2005;21:347-6.
13. Garcia-Pagan JC, Bosch J. Endoscopic band ligation in the treatment of portal hypertension . Nat Clin Pract Gastroenterol Hepatol 2005 ; 2 : 526-35.
14. Gluud LL, Klingenberg S, Nikolova D et al. Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials . Am J Gastroenterol 2007 ; 102 : 2842-8.
15. Imperiale TF, Klein RW, Chalasani N. Cost-efectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding . Hepatology 2007;45:870-8.
16. Longacre AV, Imaeda A, Garcia-Tsao G et al. A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage . Hepatology 2008 ; 47 : 169-76.
17. Turnes J, Garcia-Pagan JC, Abraldes JG et al. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis . Am J Gastroenterol 2006 ; 101 : 506-12.
18. Groszmann RJ, Garcia-Tsao G, Bosch J et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis . N Engl J Med 2005 ; 353 : 2254-61.
19. Garcia-Tsao G, Grace N, Groszmann RJ et al. Short term effects of pro-pranolol on portal venous pressure. Hepatology 1986;6:101-6.
20. Abraczinkas DR, Ookubo R, Grace ND et al. Propranolol for the prevention of first variceal hemorrhage: a lifetime commitment? Hepatology 2001 ; 34 : 1096-102.
21. DAmico G, Garcia-Tsao G, Cales P et al. Diagnosis of portal hypertension: how and when . In: DeFranchis R (eds). Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies . Blackwell Science: Oxford , 2001, pp. 36-64.
22. Shaheen NJ, Stuart E, Schmitz SM et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology 2005;41:588-94.
23. Schepke M, Kleber G, Nurnberg D et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis . Hepatology 2004;40:65-72.
24. Norberto L, Polese L, Cillo U et al. A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation . Liver Transpl 2007 ; 13 : 1272-8.
25. Garcia-Pagan JC, Villanueva C, Vila MC et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 2001;121:908-14.
26. Borroni G, Salerno F, Cazzaniga M et al. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites . J Hepatol 2002 ; 37 : 315-21.
27. Angelico M, Carli L, Piat C et al. Efects of isosorbide-5- mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis . Gastroenterology 1997 ; 113 : 1632-9.
28. Gonzalez-Abraldes J, Albillos A, Banares Ret al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382-8.
29. Schepke M, Werner E, Biecker E et al. Hemodynamic effects of the an-giotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 200;121:389-95.
30. Garcia-Pagan JC, Feu F, Bosch J et al. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study . Ann Intern Med 1991 ; 114 : 869-73.
31. Garcia-Pagan JC, Morillas R, Banares Ret al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT . Hepatology 2003 ; 37 : 1260-6.
32. DAmico G, Pasta L, Politi F et al. Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of the first bleeding in cirrhosis. A double-blind placebo-controlled randomized trial . Gastroenterol Int 2002;15:40-50.
33. Abecasis R, Kravetz D, Fassio E et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology 2003;37:359-65.
34. DAmico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review . Hepatology 1995 ; 22 : 332-54.
35. Pagliaro L, DAmico G, Sorensen TIA et al. Prevention of frst bleeding in cirrhosis. A meta-analysis of randomized clinical trials of non-surgical treatment. Ann Intern Med 1997;17:59-60.
36. The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized, single-blind, multicenter clinical trial . N Engl J Med 1991 ; 324 : 1779-84.
37. Sarin SK, Wadhawan M, Agarwal SR et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding . Am J Gastroenterol 2005 ; 100 : 797-804.
38. Gheorghe C, Gheorghe L, Iacob S et al. Primary prophylaxis of variceal bleeding in cirrhotics awaiting liver transplantation . Hepatogastroenterol-ogy 2006;53:552-7.
39. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension . Hepatology 2005 ; 41 : 386-400.
40. Tripathi D, Ferguson JW, Kochar N et al. Multicenter randomized controlled trial of carvedilol versus variceal band ligation for the prevention of first variceal bleed . Hepatology 2007 ; 46 (Suppl 1) : 269A (abstract) .
41. Black M. Acetaminophen hepatotoxicity . Annu Rev Med 1984 ; 35 : 577-93.
42. Seef LB, Cuccherini BA, Zimmerman HJ et al. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure . Ann Intern Med 1986;104:399-404.
43. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995;22:767-73.
44. Westphal JF, Brogard JM Drug administration in chronic liver disease . Drug Saf 1997 ; 17 : 47-73.
45. Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States . Ann Intern Med 2002;137:947-54.
46. Larson AM, Polson J, Fontana RJ et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study . Hepatology 2005 ; 42 : 1364-72.
47. Mirouze D, Zipser RD, Reynolds TB. Efects of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis . Hepatology 1983 ; 3 : 50-5.
48. Planas R, Arroyo V Rimola A et al. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983;84:247-52.
49. Wong F, Massie D, Hsu P et al. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis . Gastroenterology 1993 ; 104 : 869-76.
50. DeFranchis R Pascal JP, Burroughs AK et al. Defnitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop. J Hepatol 1992;15:256-61.
51. Shoema kerWC.R elation of oxygen transport patterns to the pathophysiol-ogy and therapy of shock states. Intensive Care Med 1987;13:230-43.
52. Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemody-namics in portal hypertensive rats during hemorrhage and blood volume restitution . Gastroenterology 1986 ; 90 : 1232-40.
53. Castaneda B, Morales J, Lionetti R et al. Efects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology 2001;33:821-5.
54. Hou MC, Lin HC, Liu TT et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004;39:746-53.
55. Bernard B, Grange JD, Khac EN et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis . Hepatology 1999 ; 29 : 1655-61.
56. Soares-Weiser K, Brezis M, Tur-Kaspa R et al. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding (Cochrane review) . Cochrane Database Syst Rev 2002 ; (2) : CD002907 .
57. Rimola A, Garcia-Tsao G, Navasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis a consensus document . J Hepatol 2000;32:142-53.
58. Fernandez J, Ruiz del Arbol L, Gomez C et al. Norfoxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage . Gastroenterology 2006 ; 131 : 1049 -56 .
59. Bosch J, Thabut D, Bendtsen F et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial . Gastroenterology 2004 ; 127 : 1123 -30 .
60. Bosch J, Thabut D, Albillos A et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial . Hepatology 2008 ; 47 : 1604- 14.
61. Villanueva C, Piqueras M, Aracil C et al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding . J Hepatol 2006 ; 45 : 560-7.
62. DAmico G, de Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators . Hepatology 2003 ; 38 : 599-612 .
63. Moitinho E, Escorsell A, Bandi JC et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding . Gastroenterology 1999;117:626-31.
64. Abraldes JG, Villanueva C, Banares R et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy . J Hepatol 2008 ; 48 : 229-36.
65. Sanyal AJ, Freedman AM, Luketic VA et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 996;1:138-46.
66. McCormick PA, Dick R, Panagou EB et al. Emergency transjugular intrahepatic portosystemic stent shunting as a salvage treatment for uncontrolled variceal hemorrhage . Br J Surg 1994 ; 81 : 1324-7.
67. Orlof MJ, Orlof MS, Orlof SL et al. Three decades of experience with emergency portacaval shunt for acutely bleeding esophageal varices in 400 unselected patients with cirrhosis of the liver . J Am Coll Surg 1995;180:257-72.
68. Avgerinos A, Armonis A. Balloon tamponade technique and efficacy in variceal haemorrhage . Scand J Gastroenterol Suppl 1994 ; 207 : 11-6.
69. Hubmann R, Bodlaj G, Czompo M et al. The use of self-expanding metal stents to treat acute esophageal variceal bleeding . Endoscopy 2006 ; 38 : 896-901.
70. Sarin SK, Jain AK, Jain M et al. A randomized controlled trial of cyanoacr-ylate versus alcohol injection in patients with isolated fundic varices . Am J Gastroenterol 2002 ; 97 : 1010-5.
71. Lo GH, Lai KH, Cheng JS et al. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices . Hepatology 2001 ; 33 : 1060-4.
72. Tan PC, Hou MC, Lin HC et al. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation . Hepatology 2006 ; 43 : 690-7.
73. Rengstorf DS, Binmoeller KF. A pilot study of 2-octyl cyanoacrylate injection for treatment of gastric fundal varices in humans . Gastrointest Endosc 2004;59:553-8.
74. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L et al. Infuence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding . Hepatology 2004 ; 40 : 793-801 .
75. Garcia-Pagan JC, Caca K, Bureau C et al. An early decision for PTFE-TIPS improves survival in high-risk cirrhotic patients admitted with an acute variceal bleeding: a multicenter RCT . Hepatology 2008 ; 48 (Suppl) : 373A (abstract).
76. Gonzalez R, Zamora J, Gomez-Camarero J et al. Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 2008;149:109-22.
77. Lo GH, Lai KH, Cheng JS et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial . Hepatology 2000 ; 32 : 461-5.
78. De la Pena J, Brullet E, Sanchez-Hernandez E et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial . Hepatology 2005 ; 41 : 572-8.
79. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet 2003;361:952-4.
80. DAmico G, Garcia-Pagan JC, Luca A et al. HVPG reduction and prevention of variceal bleeding in cirrhosis. A systematic review . Gastroenterology 2006 ; 131 : 1611-24.
81. Bureau C, Peron JM, Alric L et al. "A La Carte" treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding . Hepatology 2002 ; 36 : 1361-6.
82. Gonzalez A, Augustin S, Perez M et al. Hemodynamic response-guided therapy for prevention of variceal rebleeding: an uncontrolled pilot study . Hepatology 2006;44:806-12.
83. La Mura V, Abraldes JG, Retto O et al. Acute HVPG response to i.v. pro-pranolol and risk of portal hypertension related bleeding . J Hepatol 2007 ; 46 (Suppl 1) : S96 (abstract 236) .
84. Aracil C, Colomo A, Ordas I et al. Acute hemodynamic response to beta-blockers for the prediction of long-term outcome in primary prophylaxis of variceal bleeding. Final results of a prospective study . J Hepatol 2007 ; 46 (Suppl 1) : S35 (abstract 79) .
85. Gournay J, Masliah C, Martin T et al. Isosorbide mononitrate and pro-pranolol compared with propranolol alone for the prevention of variceal rebleeding . Hepatology 2000 ; 31 : 1239-45.
86. Garcia Pagan JC, Villanueva C, Albillos A et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of variceal rebleeding: a multicenter randomized controlled trial . Gut 2009 (in press) .
87. Conn HO. The rational evaluation and management of portal hypertension. . In: Schaffner F, Sherlock S, Leevy CM (eds). The Liver and its Diseases . Intercontinental: New York , 1974 , pp. 289-306.
88. Luca A, DAmico G, LaGalla R et al. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials . Radiology 1999;212:411-21.
89. Papatheodoridis GV, Goulis J, Leandro G et al. Transjugular intrahepatic portsystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding. A meta-analysis . Hepatology 1999 ; 30 : 612-22.
90. Escorsell A, Banares R, Garcia-Pagan JC et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002;35:385-92.
91. de Franchis R, Primignani M. Endoscopic treatment for portal hypertension . Semin Liv Dis 1999 ; 19 : 439-55.
92. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis . Ann Intern Med 1995;123:280-7.
93. Bosch J, Abraldes JG, Berzigotti A et al. Portal hypertension and gastrointestinal bleeding . Semin Liver Dis 2008 ; 28 : 3-25.
94. Singh P, Pooran N, Indaram A et al. Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a meta-analysis . Am J Gastroenterol 2002 ; 97 : 623-9.
95. Garcia-Tsao G Spontaneous bacterial peritonitis: a historical perspective . J Hepatol 2004;4:522-7.
96. Ghassemi S, Garcia-Tsao G Prevention and treatment of infections in patients with cirrhosis . Baillieres Best Pract Res Clin Gastroenterol 2007;21:77-93.
97. Nousbaum JB, Cadranel JF, Nahon P et al. Diagnostic accuracy of the Mul-tistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis . Hepatology 2007 ; 45 : 1275-81.
98. Xiol X, Castellvi JM, Guardiola J et al. Spontaneous bacterial empyema in cirrhotic patients: a prospective study . Hepatology 1996 ; 23 : 719-23.
99. Bobadilla M, Sifuentes J, Garcia-Tsao G Improved method for bacteriological diagnosis of spontaneous bacterial peritonitis . J Clin Microbiol 1989 ; 27 : 2145-7.
100. Fernandez J, Navasa M, Gomez J et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-8.
101. Felisart J, Rimola A, Arroyo V et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections . Hepatology 1985;5:457-62.
102. Runyon BA, McHutchison JG, Antillon MR et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis . Gastroenterology 1991 ; 100 : 1737-42.
103. Rimola A, Salmeron JM, Clemente G et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study . Hepatology 1995;21:674-9.
104. Angeloni S, Lebofe C, Parente A et al. Effcacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice . World J Gastroenterol 2008 ; 14 : 2757-62.
105. Acevedo J, Fernandez J, Castro M et al. Current efficacy of recommended empirical antibiotic therapy in patients with cirrhosis and bacterial infection . J Hepatol 2009; 50 (Suppl 1): (abstract) .
106. Gomez-Jimenez J, Ribera E, Gasser I et al. Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients . Antimicrob Agents Chemother 1993 ; 37 : 1587-92.
107. Mesquita MA, Balbino EPS, Abuquerque RS et al. Cefriaxone in the treatment of spontaneous bacterial peritonitis: ascitic fluid polymorpho-nuclear count response and short-term prognosis . Hepatogastroenterology 1997 ; 44 : 1276-80.
108. Ricart E, Soriano G, Novella M et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients . J Hepatol 2000;32:596-602 .
109. Umgelter A, Reindl W, Miedaner M et al. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection 2009;37:2-8.
110. Llovet JM, Rodriguez-Iglesias P, Moitinho E et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997;26:88-95.
111. Sort P, Navasa M, Arroyo V et al. Efect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis . N Engl J Med 1999 ; 341 : 403-9.
112. Chen TA, Tsao YC, Chen A et al. Efect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis . Scand J Gastroenterol 2009;4:-7.
113. Sigal SH, Stanca CM, Fernandez J et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007;56:597-9.
114. Terg R, Gadano A, Cartier M et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study . Liver Int 2009 ; 29 : 415-9.
115. Casas M, Soriano G, Ayala E et al. Intravenous albumin is not necessary in cirrhotic patients with spontaneous bacterial peritonitis and low-risk of mortality . J Hepatol 2007 ; 46 (Suppl 1) : S91 (abstract) .
116. Fong TL, Akriviadis EA, Runyon BA et al. Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology 1989;9:423-6.
117. Garcia-Tsao G Spontaneous bacterial peritonitis. In: Weinstein WM, Hawkey CJ, Bosch J (eds). Clinical Gastroenterology and Hepatology . Elsevier: Philadelphia, PA , 2005 , pp. 723-8.
118. Terg R, Cobas S, Fassio E et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study . J Hepatol 2000 ; 33 : 564-9.
119. Angeli P, Guarda S, Fasolato S et al. Switch therapy with ciprofoxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost . Aliment Pharmacol Ther 2006;23:75-84.
120. Garcia-Tsao G Further evidence against the use of aminoglycosides in cirrhotic patients . Gastroenterology 1998 ; 114 : 612-3.
121. Navasa M, Follo A, Llovet JM et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis . Gastroenterology 1996 ; 111 : 1011-7.
122. Ruiz del Arbol L, Monescillo A, Jimenez W et al. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis . Gastroenterology 1997 ; 113 : 579 -86 .
123. Gines P, Rimola A, Planas Ret al. Norfoxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial . Hepatology 1990 ; 12 : 716-24.
124. Tito L, Rimola A, Gines P et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors . Hepatology 1988;8:27-31. 25 . Bauer TM, Fol lo A, Navasa M et al. Daily norfoxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence . Dig Dis Sci 2002 ; 47 : 1356-6.
125. Rolachon A, Cordier L, Bacq Y et al. Ciprofoxacin and long-term prevention of spontaneous bacterial peritonitis. Results of a prospective controlled trial . Hepatology 1995 ; 22 : 1171-4.
126. Terg R, Llano K, Cobas SM et al. Efects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis - Results of short-and long-term administration with daily and weekly dosages . J Hepatol 1998;29:437-42.
127. Singh N, Gayowski T, Yu VL et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995;122:595-8.
128. Ratnof OD, Patek AJ. The natural history of Laennec's cirrhosis of the liver: an analysis of 386 cases . Medicine 1942 ; 21 : 207-68.
129. Powell WJ, Klatskin G Duration of survival in patients with Laennec's cirrhosis . Am J Med 1968 ; 44 : 406-20.
130. Llach J, Gines P, Arroyo V et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites . Gastroenterology 1988;94:482-7.
131. Salerno F, Borroni G, Moser P et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients . Am J Gastroenterol 1993;88:514-9.
132. Gines A, Escorsell A, Gines P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites . Gastroenterology 1993;105:229-36.
133. Bosch-Marce M, Claria J, Titos E et al. Selective inhibition of cyclooxyge-nase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites . Gastroenterology 1999 ; 116 : 1167 -76 .
134. Guevara M, Abecasis R, Terg R. Efect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study . Scand J Gastroenterol 2004;39:385-6.
135. Novella M, Sola R, oriano G et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin . Hepatology 1997 ; 25 : 532-6.
136. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis . Gastroenterology 1986 ; 91 : 1343-6.
137. Grange JD, Roulot D, Pelletier G et al. Norfoxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites - a double-blind randomized trial . J Hepatol 1998 ; 29 : 430-6.
138. Terg R, Fassio E, Guevara M et al. Ciprofoxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study . J Hepatol 2008;48:774-9.
139. Fernandez J, Navasa M, Planas R et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis . Gastroenterology 2007 ; 133 : 818-24
140. Moore KP, Wong F, Gines P et al. The management of ascites in cirrhosis: Report On the Consensus Conference of the International Ascites Club . Hepatology 2003;38:258-66.
141. Fogel MR, Sawhney VK, Neal A et al. Diuresis in the ascitic patient: a randomized controlled trial of three regimens . J Clin Gastroenterol 1981 ; 3 (Suppl 1) : 73-80.
142. Perez-Ayuso RM, Arroyo V, Planas R et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system . Gastroenterology 1983 ; 84 : 961-8.
143. Santos J, Planas R, Pardo A et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety . J Hepatol 2003;39:87-92.
144. Gines P, Arroyo V, Quintero E et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology 1987;93:234-41.
145. Salerno F, Badalamenti S, Incerti P et al. Repeated paracentesis and i.v. albumin infusion to treat " tense " ascites in cirrhotic patients: a safe alternative therapy. J Hepatol 1987;5:102-8.
146. Tito L, Gines P, Arroyo V et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites . Gastroenterology 990;98:146-51.
147. Sola R, Vila MC, Andreu M et al. Total paracentesis with dextran 40 vs. diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. J Hepatol 994;20:282-8.
148. Angeli P, Dalla Pria M, DeBei E et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites . Hepatology 1994 ; 19 : 72-9.
149. Lenaerts A, Codden T, Meunier JC et al. Efects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system . Hepatology 2006 ; 44 : 844-9.
150. Jimenez W, Gal CS, Ros J et al. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats . J Pharmacol Exp Ther 2000;295:83-90.
151. Ros J, Fernandez-Varo G, Munoz-Luque J et al. Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention . Br J Pharmacol 2005 ; 146 : 654-61. 153 . GerbesAL, GulbergV, G nes P et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multi-center trial . Gastroenterology 2003 ; 124 : 933-9.
152. Gines P, Wong F, Watson H et al. Efects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B) in patients with cirrhosis and ascites without hyponatremia . Hepatology 2006 ; 44 (Suppl 1) : 445A .
153. Angeli P, Wong F, Watson H et al. Hyponatremia in cirrhosis: results of a patient population survey . Hepatology 2006 ; 44 : 1535-42.
154. Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management . Hepatology 2008 ; 48 : 1002-10.
155. Heuman DM, Abou-Assi SG, Habib A et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death . Hepatology 2004 ; 40 : 802- 10.
156. Kim WR, Biggins SW, Kremers WK et al. Hyponatremia and mortality among patients on the liver-transplant waiting list . N Engl J Med 2008 ; 359 : 1018-26.
157. McCormick PA, Mistry P, Kaye G et al. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites . Gut 1990;3:204-7.
158. Wong F, Blei AT, Blendis LM et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial . Hepatology 2003;37:82-91.
159. Schrier RW Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia . N Engl J Med 2006 ; 355 : 2099-12 .
160. Gines P, Wong F, Watson H et al. Efects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial . Hepatology 2008 ; 48 : 204-13.
161. Planas R, Montoliu S, Balleste B et al. Natural history of patients hospitalized for management of cirrhotic ascites . Clin Gastroenterol Hepatol 2006 ; 4 : 1385-94.
162. Arroyo V, Gines P, Gerbes AL et al. Defnition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis . Hepatology 1996;23:64-76.
163. Peltekian KM, Wong F, Liu PP et al. Cardiovascular, renal, and neuro-humoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites . Am J Gastroenterol 1997 ; 92 : 394-9.
164. Gines P, Arroyo V, Vargas V et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites . N Engl J Med 1991 ; 325 : 829-35.
165. Gines A, Fernandez-Esparrach G, Monescillo A et al. Randomized trial comparing albumin, dextran-70 and polygeline in cirrhotic patients with ascites treated by paracentesis . Gastroenterology 1996 ; 111 : 1002-10.
166. DAmico G, Luca A, Morabito A et al. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis . Gastroenterology 2005 ; 129 : 1282-93.
167. Albillos A, Banares R, Gonzalez M et al. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites . J Hepatol 2005;43:990-6.
168. Salerno F, Camma C, Enea M et al. Transjugular intrahepatic
169. Bureau C, Garcia-Pagan JC, Otal P et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004;26:469-75.
170. Garcia-Tsao G. The transjugular intrahepatic portosystemic shunt for the management of refractory ascites . Nat Clin Pract Gastroenterol Hepatol 2006;3:380-9.
171. Gines A, Planas R, Angeli P et al. Treatment of patients with cirrhosis and refractory ascites by LeVeen shunt with titanium tip. Comparison with therapeutic paracentesis . Hepatology 1995 ; 22 : 124-31.
172. Dumortier J, Pianta E, Le Derf Y et al. Peritoneovenous shunt as a bridge to liver transplantation . Am J Transplant 2005 ; 5 : 1886-92.
173. Liu LU, Haddadin HA, Bodian CA et al. Outcome analysis of cirrhotic patients undergoing chest tube placement . Chest 2004 ; 126 : 142-8.
174. Lenaerts A, Codden T, Henry JP et al. Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine- spironolactone in the treatment of cirrhosis-associated refractory ascites . Gastroenterol Clin Biol 2005 ; 29 : 1137-42.
175. Wong F, Gines P, Watson H et al. Efects of a selective vasopressin V2 receptor antagonist, satavaptan (SR121463B) on recurrence of ascites after large volume paracentesis . Hepatology 2006 ; 44 (Suppl 1) : 256A .
176. Angeli P, Volpin R, Piovan D et al. Acute efects of the oral administration of midodrine, an a-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites . Hepatology 1998 ; 28 : 937-43.
177. Kalambokis G, Fotopoulos A, Economou M et al. Efects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007;46:213-2.
178. Krag A, Moller S, Henriksen JH et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome . Hepatology 2007 ; 46 : 1863-71.
179. Zanditenas D, Condat B, Blazquez M et al. Efects of prolonged administration of midodrine in the treatment of diuretic-resistant ascites: a pilot study . J Hepatol 2007 ; 46 (Suppl 1) : S101 (abstract 251) .
180. Tandon P, Tsuyuki RT, Mitchell L et al. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int 2009;29:169-74.
181. Moreau R, Asselah T, C ondat B et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomized pilot study . Gut 2002 ; 50 : 90-4.
182. Singh V, Kumar R, Nain CK et al. Terlipressin versus albumin in paracen-tesis-induced circulatory dysfunction in cirrhosis: a randomized study . J Gastroenterol Hepatol 2006;21:303-7.
183. Singh V, Dheerendra PC, Singh B et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study . Am J Gastroenterol 2008 ; 103 : 1399-405 .
184. Appenrodt B, Wolf A, Grunhage F et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study Liver Int 2008 ; 28 : 1019-25.
185. Salerno F, Gerbes A, Gines P et al. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club . Gut 2007 ; 56 : 1310-8.
186. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis . Hepatology 2008 ; 48 : 2064-77.
187. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome . Semin Liver Dis 2008 ; 28 : 81-95.
188. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury . Crit Care 2007 ; 11 : R31 Published online doi: 10.1186/cc5713. PMCID: PMC2206446) .
189. SchrierRW, Arroyo V, Bernardi M et al. Peripheral arterial vasodilation hypothesis - a proposal for the initiation of renal sodium and water retention in cirrhosis . Hepatology 1988 ; 8 : 1151-7.
190. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome . Hepatology 2004;40:55-64.
191. Sanyal AJ, Boyer T, Garcia-Tsao G et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome . Gastroenterology 2008 ; 134 : 1360-8.
192. Martin-Llahi M, Pepin MN, Guevara M et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study . Gastroenterology 2008 ; 134 : 1352-9.
193. Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis . Best Pract Res Clin Gastroenterol 2007 ; 21 : 11-23.
194. Wiesner R, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers . Gastroenterology 2003 ; 124 : 91-6.
195. Rimola A, Gavaler JS, Schade RR et al. Efects of renal impairment on liver transplantation. Gastroenterology 1987;93:148-56.
196. Gonwa TA, Klintmalm GB, Levy M et al. Impact of pre transplant renal function on survival after liver transplantation . Transplantation 1995;59:361-5.
197. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation . Hepatology 2002 ; 35 : 1179 -85 .
198. Gonwa TA, McBride MA, Anderson K et al. Continued influence of pre-operative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006 ; 6 : 2651-9.
199. Restuccia T, Ortega R, Guevara M et al. Efects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004;40:140-6. 202 . Solanki P, Ch awla A, Garg R et al. Benefcial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial . J Gastroenterol Hepatol 2003 ; 18 : 152-6.
200. Neri S, Pulvirenti D, Malaguarnera M et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome . Dig Dis Sci 2008;53:830-5.
201. Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type I heparorenal syndrome: a retrospective multicenter study . Gastroenterology 2002;122:923-30.
202. Kiser TH, Fish DN, Obritsch MD et al. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study . Nephrol Dial Transplant 2005 ; 20 : 1813-20.
203. Alessandria C, Ottobrelli A, Debernardi-Venon W et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study . J Hepatol 2007 ; 47 : 499-505 .
204. Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide . Hepatology 1999 ; 29 : 1690-7.
205. Esrailian E, Pantangco ER, Kyulo NL et al. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome . Dig Dis Sci 2007 ; 52 : 742-8.
206. Runyon BA. Management of adult patients with ascites due to cirrhosis . Hepatology 2004;39:841-56.
207. Guevara M, Gines P, Bandi JC et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems . Hepatology 1998 ; 28 : 416-22.
208. Brensing KA, Textor J, Perz J et al. Long-term outcome afer transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study . Gut 2000 ; 47 : 288-95.
209. Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomized, controlled clinical trial . Liver Transpl 2000;6:277-86.
210. Arief A, Chidsey CA. Renal function in cirrhosis and the effects of pros-taglandin A1 . Am J Med 1974 ; 56 : 695-703.
211. Fevery J, Van Cutsem E, Nevens F et al. Reversal of hepatorenal syndrome in four patients with peroral misoprostol (prostaglandin E1 analogue) and albumin administration . J Hepatol 1990 ; 11 : 153-8.
212. Gines A, Salmeron JM, Gines P et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure . J Hepatol 1993 ; 17 : 220-6.
213. Barnardo DE, Baldus WP, Maher FT. Efects of dopamine on renal function in patients with cirrhosis . Gastroenterology 1970 ; 58 : 524-31.
214. Bennet WM, Keefe E, Melnyk C et al. Response to dopamine hydrochlo-ride in the hepatorenal syndrome . Arch Intern Med 1975 ; 135 : 964 -71 .
215. Salo J, Gines A, Quer JC et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome . J Hepatol 1996;25:916-23.
216. Pomier-Layrargues G, Paquin SC, Hassoun Z et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study . Hepatology 2003 ; 38 : 238-43.
217. Ferenci P, Lockwood A, Mullen KD et al. Hepatic encephalopathy - defi-nition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998 . Hepatology 2002 ; 35 : 716-2.
218. Morgan MY, Blei A, GrungreifK et al. The treatment of hepatic encepha-lopathy . Metab Brain Dis 2007 ; 22 : 389-405 .
219. Restuccia T, Gomez-Anson B, Guevara M et al. Efects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis . Hepatology 2004 ; 39 : 1613-22.
220. Cordoba J, Blei AT. Treatment of hepatic encephalopathy. Am J Gastroen-terol 1997 ; 92 : 1429-39.
221. Cordoba J, Minguez B. Hepatic encephalopathy . Semin Liver Dis 2008;28:70-80.
222. Cordoba J, Lopez-Hellin J, Planas M et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study . J Hepatol 2004;4:38-43.
223. Mullen KD, Dasarathy S. Protein restriction in hepatic encephalopathy: necessary evil or illogical dogma? J Hepatol 2004 ; 41 : 147-8.
224. Fessel JN, Conn HO. An analysis of the causes and prevention of hepatic coma. Gastroenterology 1972;62:19.
225. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials . BMJ 2004 ; 328 : 1046 (Published online doi: 10.1136/bmj.38048.506134.EE. PMCID: PMC403844) .
226. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial . Am J Dig Dis 1978 ; 23 : 398-406 .
227. Mas A, Rodes J, Sunyer L et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial . J Hepatol 2003;38:51-8.
228. Paik YH, Lee KS, Han KH et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study . Yonsei Med J 2005 ; 46 : 399-407 .
229. Jiang Q, Jiang XH, Zheng MH et al. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis . Eur J Gastroenterol Hepatol 2008 ; 20 : 1064-70.
230. Goulenok C, Bernard B, Cadranel JF et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis . Aliment Pharmacol Ther 2002;16:361-72.
231. Als-Nielsen B, Kjaergard LL, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy . Cochrane Database Syst Rev (computer file) 2001 ; 4 : CD002798 .
232. Hassanein TI, Tofeng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis . Hepatology 2007 ; 46 : 1853 -62 .
233. Plauth M, Cabre E, Riggio O et al. ESPEN Guidelines on Enteral Nutrition: liver disease . Clin Nutr 2006 ; 25 : 285-94.
234. Merli M, Riggio O. Dietary and nutritional indications in hepatic encephalopathy . Metab Brain Dis 2009 ; 24 : 211-21.
235. Riggio O, Masini A, Efrati C et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study . J Hepatol 2005 ; 42 : 674-9.
236. Huang E, Esrailian E, Spiegel BM The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis . Aliment Pharmacol Ther 2007 ; 26 : 1147-61.
237. Loguercio C, Abbiati R, Rinaldi M et al. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1 -2 hepatic encephalopathy . J Hepatol 1995 ; 23 : 39-46.
238. Liu Q, Duan ZP, Ha dK et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis . Hepatology 2004 ; 39 : 1441-9.
239. El Serag HB, Davila JA, Petersen NJ et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update . Ann Intern Med 2003;39:817-23.
240. Leykum LK, El Serag HB, Cornell J et al. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival . Clin Gastroenterol Hepatol 2007 ; 5 : 508-12.
241. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 ; 42 : 1208-36.
242. Zhang BH, Yang BH, Tang ZY Randomized controlled trial of screening for hepatocellular carcinoma . J Cancer Res Clin Oncol 2004 ; 130 :
243. Wang P, Meng ZQ, Chen Z et al. Diagnostic value and complications of fine needle aspiration for primary liver cancer and its influence on the treatment outcome-a study based on 3011 patients in China . Eur J Surg Oncol 2008 ; 34 : 541-6.
244. Crowe DR, Eloubeidi MA, Chhieng DC et al. Fine-needle aspiration biopsy of hepatic lesions: computerized tomographic-guided versus endo-scopic ultrasound-guided FNA . Cancer 2006 ; 108 : 180-5.
245. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification . Semin Liv Dis 1999 ; 19 : 329-38.
246. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation . Hepatology 1999 ; 30 : 1434-40.
247. Bruix J, Castells A, Bosch J et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients. Prognostic value of preoperative portal pressure . Gastroenterology 1996 ; 111 : 1018-22.
248. Ishizawa T, Hasegawa K, Aoki T et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma . Gastroenterology 2008 ; 134 : 1908 -16 .
249. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis . N Engl J Med 1996;334:693-9.
250. Freeman RB, Wiesner RH, Edwards E et al. Results of the first year of the new liver allocation plan . Liver Transpl 2004 ; 10 : 7-15.
251. Gondolesi GE, Roayaie S, Munoz L et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria . Ann Surg 2004 ; 239 : 142-9.
252. Lin SM, Lin CJ, Lin CC et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm . Gastroenterology 2004 ; 127 : 1714-23.
253. Lencioni RA, Allgaier HP, Cioni D et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection . Radiology 2003 ; 228 : 235 -40 .
254. Llovet JM, Bruix J. Systematic review of randomized trials for unresect-able hepatocellular carcinoma: chemoembolization improves survival . Hepatology 2003;37:429-42.
255. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma . N Engl J Med 2008 ; 359 : 378 -90 .
256. Cheng AL, Kang YK, Chen Z et al. Effcacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial . Lancet Oncol 2009 ; 10 : 25-34.